"Metronomic Scheduling: The Next Generation of Multi-Target Therapy"

Overview

5th Biennial "International Metronomic & Anti-Angiogenic Meeting" to be organized from 6th to 8th May 2016. This meeting is being organized by Dept. Of Medical Oncology of TMH as part of the 75th year celebrations of Tata Memorial Centre under the aegis of MGHI, ICON, and ISMPO.

About Symposium

5th Biennial “International Metronomic & Anti-Angiogenic Meeting” to be organized from 6th to 8th May 2016. This meeting is being organized by Dept. Of Medical Oncology of TMH as part of the 75th year celebrations of Tata Memorial Centre under the aegis of MGHI, ICON, and ISMPO.

Even after waging the "war against cancer" for years, most of the advanced cancers are still not curable. Metronomic Rescheduling of Anticancer Treatment (MSAT)has now grown beyond the anticipated scope of anti-angiogenic chemotherapy with accumulating evidence

demonstrating that these treatments may also act by stimulating an antitumor immune response and could ultimately lead to re-induction of tumor dormancy. The concept of MSAT is no longer a laboratory restricted idea. As of 2014, there are more than 150 registered clinical trials in various stages of development examining metronomic therapy and its efficacy. This reiterates the growing interest in this area of cancer directed therapy. What widens the reach of metronomic chemotherapy is its potential ability to be combined with conventional cytotoxic chemotherapy & newer targeted therapies.

Partners and Sponsors

Contact

  • R.R. Choksi Auditorium,
    Tata Memorial Hospital,
    Parel, Mumbai. India.
  • event@metronomicsmumbai.com
  • Dr. Shripad Banavali - 9820074514
  • Dr. Vijay Patil - 9869382266
  • Ms. Leena Walvankar - 9773862355